Sunshine Biopharma Plans to Offer 5.825M Common Units
Sunshine Biopharma is offering, on a best efforts basis, up to 5.825M common units, each common unit consisting of one share of common stock, and two Series C warrants, each Series C warrant exercisable for one share of common stock.
Trade with 70% Backtested Accuracy
Analyst Views on SBFM
About SBFM
About the author
Sunshine Biopharma Raises $6 Million in Public Offering
- Financing Structure: Sunshine Biopharma has priced a public offering of 12 million common units at $0.50 each, raising a total of $6 million, with closing expected on May 19, 2026, thereby strengthening its cash position for future growth.
- Shareholder Rights: Each common unit consists of one share of common stock and two Series C warrants, which are exercisable immediately at $0.50 per share for five years, enhancing potential returns for investors.
- Market Performance: The company's stock surged 79.51% in yesterday's trading to close at $0.51, although it fell 5.57% in after-hours trading, reflecting a positive market reaction to the new financing amid short-term volatility.
- Product Expansion: Sunshine currently markets 60 generic prescription drugs in Canada and plans to launch 12 additional products in 2026, while also advancing two proprietary drug programs aimed at expanding its footprint in oncology and antiviral therapeutics.
Sunshine Biopharma Reports FY Revenue of $36.3M
- Annual Revenue Performance: Sunshine Biopharma reported FY revenue of $36.3 million, indicating stable growth in the biopharmaceutical sector, reflecting increasing market acceptance and demand for its products.
- Funding for Expansion: The company raised $2.46 million in gross proceeds through a registered direct offering, which will support the expansion of sales operations aimed at increasing market share and enhancing competitiveness.
- Product Portfolio Expansion: Nine new generic prescription drugs have been launched, covering oncology, cardiovascular health, central nervous system disorders, and antimicrobials, further enriching the product line and meeting diverse patient needs.
- Positive Market Outlook: With the introduction of new drugs and the expansion of sales operations, Sunshine Biopharma is poised for higher revenue growth in the future, strengthening its market position in the biopharmaceutical industry.
Aegis Capital Affirms Buy Rating for Sunshine Biopharma, Keeps $7 Price Target Intact
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
- Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights from Benzinga reporters.
3 Penny Stocks to Watch Now, 4/3/25
Penny Stocks to Watch: Sportsman’s Warehouse, Sunshine Biopharma, and ConnectM Technology Solutions are highlighted as top penny stocks on April 3, 2025, based on their high Dollar Volume and significant stock price movements following positive company news.
Company Highlights: Sportsman’s Warehouse saw a nearly 98% increase in stock price after strong Q4 results; Sunshine Biopharma reported a 45% revenue increase and positive study results; ConnectM Technology's shares surged due to a buyout proposal amid delisting concerns.
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Stock Performance: Sunshine Biopharma Inc. (SBFM) saw a significant increase in stock price, rising 69.2% to $3.52, with trading volume reaching 19.07 million shares on Wednesday, compared to an average of 88.16K.
Research Advancements: The company announced successful studies on its K1.1 mRNA Lipid Nanoparticle product for treating human hepatocellular carcinoma, demonstrating effective tumor growth reduction and promising results for both full-length and truncated mRNA versions in mouse models.
US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia
Market Overview: U.S. stock futures fell following a mixed trading session, with major indices down in premarket as traders await President Trump's announcement on potential tariffs that could impact a significant portion of imports.
Economic Insights: Analysts express concerns over market uncertainty and the potential for increased volatility due to tariff implications, while also noting significant losses in major indices for March and the first quarter of the year.
Sunshine Biopharma Raises $6 Million in Public Offering
- Financing Structure: Sunshine Biopharma has priced a public offering of 12 million common units at $0.50 each, raising a total of $6 million, with closing expected on May 19, 2026, thereby strengthening its cash position for future growth.
- Shareholder Rights: Each common unit consists of one share of common stock and two Series C warrants, which are exercisable immediately at $0.50 per share for five years, enhancing potential returns for investors.
- Market Performance: The company's stock surged 79.51% in yesterday's trading to close at $0.51, although it fell 5.57% in after-hours trading, reflecting a positive market reaction to the new financing amid short-term volatility.
- Product Expansion: Sunshine currently markets 60 generic prescription drugs in Canada and plans to launch 12 additional products in 2026, while also advancing two proprietary drug programs aimed at expanding its footprint in oncology and antiviral therapeutics.
Sunshine Biopharma Reports FY Revenue of $36.3M
- Annual Revenue Performance: Sunshine Biopharma reported FY revenue of $36.3 million, indicating stable growth in the biopharmaceutical sector, reflecting increasing market acceptance and demand for its products.
- Funding for Expansion: The company raised $2.46 million in gross proceeds through a registered direct offering, which will support the expansion of sales operations aimed at increasing market share and enhancing competitiveness.
- Product Portfolio Expansion: Nine new generic prescription drugs have been launched, covering oncology, cardiovascular health, central nervous system disorders, and antimicrobials, further enriching the product line and meeting diverse patient needs.
- Positive Market Outlook: With the introduction of new drugs and the expansion of sales operations, Sunshine Biopharma is poised for higher revenue growth in the future, strengthening its market position in the biopharmaceutical industry.
Aegis Capital Affirms Buy Rating for Sunshine Biopharma, Keeps $7 Price Target Intact
- Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
- Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights from Benzinga reporters.
3 Penny Stocks to Watch Now, 4/3/25
Penny Stocks to Watch: Sportsman’s Warehouse, Sunshine Biopharma, and ConnectM Technology Solutions are highlighted as top penny stocks on April 3, 2025, based on their high Dollar Volume and significant stock price movements following positive company news.
Company Highlights: Sportsman’s Warehouse saw a nearly 98% increase in stock price after strong Q4 results; Sunshine Biopharma reported a 45% revenue increase and positive study results; ConnectM Technology's shares surged due to a buyout proposal amid delisting concerns.
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Stock Performance: Sunshine Biopharma Inc. (SBFM) saw a significant increase in stock price, rising 69.2% to $3.52, with trading volume reaching 19.07 million shares on Wednesday, compared to an average of 88.16K.
Research Advancements: The company announced successful studies on its K1.1 mRNA Lipid Nanoparticle product for treating human hepatocellular carcinoma, demonstrating effective tumor growth reduction and promising results for both full-length and truncated mRNA versions in mouse models.
US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia
Market Overview: U.S. stock futures fell following a mixed trading session, with major indices down in premarket as traders await President Trump's announcement on potential tariffs that could impact a significant portion of imports.
Economic Insights: Analysts express concerns over market uncertainty and the potential for increased volatility due to tariff implications, while also noting significant losses in major indices for March and the first quarter of the year.
